Controlling the Nongenomic Actions of 1,25 (OH)2D3

Abstract

1a, 25-Dihydroxyvitamin D3 [1,25(OH)2D3] is a potential therapeutic agent for treatment of many clinical disorders, but its tendency to produce hypercalcemia at therapeutic dosages is a barrier to its usefulness. Derivatives of 1,25(OH)2D3 have been synthesized that possess the beneficial genomic activities of 1,25(OH)2D3 but have reduced nongenomic effects, which may be correlated with a tendency to produce hypercalcemia. </jats:p